Development of phospholipid complex loaded self-microemulsifying drug delivery system to improve the oral bioavailability of resveratrol

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Creasy LL, Creasy MT. Grape chemistry and the significance of resveratrol: an overview. Pharm. Biol. 36(5), 8–13 (1998).
  CASGoogle Scholar
• 2. Malhotra A, Bath S, Elbarbry F. An organ system approach to explore the antioxidative, anti-inflammatory, and cytoprotective actions of resveratrol. Oxid. Med. Cell. Longev. 2015, 803971 (2015).
  MedlineGoogle Scholar
• 3. Huang XL, Dai YQ, Cai JX et al. Resveratrol encapsulation in core-shell biopolymer nanoparticles: impact on antioxidant and anticancer activities. Food Hydrocolloids 64, 157–165 (2017).
  CASGoogle Scholar
• 4. Oh WY, Shahidi F. Antioxidant activity of resveratrol ester derivatives in food and biological model systems. Food Chem. 261, 267–273 (2018).
  Medline CASGoogle Scholar
• 5. Zordoky BNM, Robertson IM, Dyck JRB. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim. Biophys. Acta 1852(6), 1155–1177 (2015).
  Medline CASGoogle Scholar
• 6. Guo NH, Fu X, Zi FM, Song Y, Wang S, Cheng J. The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. Int. Immunopharmacol. 73, 181–192 (2019).
  Medline CASGoogle Scholar
• 7. Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acta 1852(6), 1071–1113 (2015).
  Medline CASGoogle Scholar
• 8. Ahmadi R, Ebrahimzadeh MA. Resveratrol – a comprehensive review of recent advances in anticancer drug design and development. Eur. J. Med. Chem. 200 (2020).
  Google Scholar
• 9. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification – the correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm. Res. 12(3), 413–420 (1995). • Explanation of the classification scheme of biopharmaceutics drug based on the solubility and bioavailability of drugs.
  Medline CASGoogle Scholar
• 10. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J. Control. Release 158(2), 182–193 (2012).
  Medline CASGoogle Scholar
• 11. Kumpugdee-Vollrath M, Ibold Y. Increasing solubility of poorly water soluble drug resveratrol by surfactants and cyclodextrins. Adv. Mater. Res. 418–420, 2231–2234 (2012).
  CASGoogle Scholar
• 12. Donsi F, Sessa M, Mediouni H, Mgaidi A, Ferrari G. Encapsulation of bioactive compounds in nanoemulsion-based delivery systems. Proc. Food Sci. 1, 1666–1671 (2011).
  CASGoogle Scholar
• 13. Wen Q, Zhang Y, Luo J et al. Therapeutic efficacy of thermosensitive pluronic hydrogel for codelivery of resveratrol microspheres and cisplatin in the treatment of liver cancer ascites. Int. J. Pharm. 582, 119334 (2020).
  Medline CASGoogle Scholar
• 14. Neves AR, Lucio M, Martins S, Lima JLC, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomedicine 8, 177–187 (2013).
  MedlineGoogle Scholar
• 15. Caddeo C, Teskac K, Sinico C, Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int. J. Pharm. 363(1–2), 183–191 (2008).
  Medline CASGoogle Scholar
• 16. Sinico C, Pireddu R, Pini E et al. Enhancing topical delivery of resveratrol through a nanosizing approach. Planta Med. 83(5), 476–481 (2017).
  Medline CASGoogle Scholar
• 17. Zhao XY, Shi CY, Zhou XY et al. Preparation of a nanoscale dihydromyricetin–phospholipid complex to improve the bioavailability: in vitro and in vivo evaluations. Eur. J. Pharm. Sci. 138 (2019).
  MedlineGoogle Scholar
• 18. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330(1–2), 155–163 (2007).
  Medline CASGoogle Scholar
• 19. Yue PF, Yuan HL, Li XY, Yang M, Zhu WF. Process optimization, characterization and evaluation in vivo of oxymatrine–phospholipid complex. Int. J. Pharm. 387(1–2), 139–146 (2010).
  Medline CASGoogle Scholar
• 20. Jiang QK, Yang XX, Du P, Zhang HF, Zhang TH. Dual strategies to improve oral bioavailability of oleanolic acid: enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. Eur. J. Pharm. Biopharm. 99, 65–72 (2016).
  Medline CASGoogle Scholar
• 21. Spernath A, Aserin A. Microemulsions as carriers for drugs and nutraceuticals. Adv. Colloid Interface Sci. 128, 47–64 (2006).
  MedlineGoogle Scholar
• 22. Kang BK, Lee JS, Chon SK et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm. 274(1–2), 65–73 (2004).
  Medline CASGoogle Scholar
• 23. Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech 11(1), 314–321 (2010).
  Medline CASGoogle Scholar
• 24. Wang LZ, Yan WR, Tian YR, Xue HH, Tang JK, Zhang LW. Self-microemulsifying drug delivery system of phillygenin: formulation development, characterization and pharmacokinetic evaluation. Pharmaceutics 12(2), 130 (2020).
  Medline CASGoogle Scholar
• 25. Nasr A, Gardouh A, Ghorab M. Novel Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics 8(3), 20 (2016).
  Google Scholar
• 26. Dhumal DM, Akamanchi KG. Self-microemulsifying drug delivery system for camptothecin using new bicephalous heterolipid with tertiary-amine as branching element. Int. J. Pharm. 541(1–2), 48–55 (2018).
  Medline CASGoogle Scholar
• 27. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16(4–5), 237–246 (2002).
  Medline CASGoogle Scholar
• 28. Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13(4), 528–534 (1996). •• Discusses surfactants in pharmaceutical formulations may enhance the intestinal absorption of some drugs by inhibiting the efflux system.
  Medline CASGoogle Scholar
• 29. Nerurkar MM, Ho NFH, Burton PS, Vidmar TJ, Borchardt RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86(7), 813–821 (1997).
  Medline CASGoogle Scholar
• 30. Qi XL, Qin JY, Ma N, Chou XH, Wu ZH. Solid self-microemulsifying dispersible tablets of celastrol: formulation development, charaterization and bioavailability evaluation. Int. J. Pharm. 472(1–2), 40–47 (2014).
  Medline CASGoogle Scholar
• 31. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int. J. Pharm. 167(1–2), 155–164 (1998).
  CASGoogle Scholar
• 32. Liu WL, Tian R, Hu WJ et al. Preparation and evaluation of self-microemulsifying drug delivery system of baicalein. Fitoterapia 83(8), 1532–1539 (2012).
  Medline CASGoogle Scholar
• 33. Zhang KX, Gu LQ, Chen JP et al. Preparation and evaluation of kaempferol-phospholipid complex for pharmacokinetics and bioavailability in SD rats. J. Pharm. Biomed. Anal. 114, 168–175 (2015).
  Medline CASGoogle Scholar
• 34. Davidov-Pardo G, Mcclements DJ. Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci. Tech. 38(2), 88–103 (2014).
  CASGoogle Scholar
• 35. Wang M, You SK, Lee HK et al. Development and evaluation of docetaxel-phospholipid complex loaded self-microemulsifying drug delivery system: optimization and in vitro/ex vivo studies. Pharmaceutics 12(6), 544 (2020).
  CASGoogle Scholar
• 36. Visetvichaporn V, Kim KH, Jung K, Cho YS, Kim DD. Formulation of self-microemulsifying drug delivery system (SMEDDS) by D-optimal mixture design to enhance the oral bioavailability of a new cathepsin K inhibitor (HL235). Int. J. Pharm. 573, 118772 (2020).
  Medline CASGoogle Scholar
• 37. Liu CR, Tong PY, Yang RJ, You YN, Liu HZ, Zhang TH. Solidified phospholipid-TPGS as an effective oral delivery system for improving the bioavailability of resveratrol. J. Drug Deliv. Sci. Technol. 52, 769–777 (2019).
  CASGoogle Scholar
• 38. Kanwal T, Kawish M, Maharjan R et al. Design and development of permeation enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for ceftriaxone sodium improved oral pharmacokinetics. J. Mol. Liq. 289, 111098 (2019).
  CASGoogle Scholar
• 39. Patel MH, Sawant KK. Self microemulsifying drug delivery system of lurasidone hydrochloride for enhanced oral bioavailability by lymphatic targeting: in vitro, Caco-2 cell line and in vivo evaluation. Eur. J. Pharm. Sci. 138, 105027 (2019).
  Medline CASGoogle Scholar
• 40. Harikumar KB, Aggarwal BB. Resveratrol - A multitargeted agent for age-associated chronic diseases. Cell Cycle 7(8), 1020–1035 (2008).
  Medline CASGoogle Scholar
• 41. Walle T. Bioavailability of resveratrol. Ann. NY Acad. Sci. 1215, 9–15 (2011).
  Medline CASGoogle Scholar
• 42. Li J, Wang XL, Zhang T et al. A review on phospholipids and their main applications in drug delivery systems. Asian J. Pharm. Sci. 10(2), 81–98 (2015).
  CASGoogle Scholar
• 43. Khan J, Alexander A, Ajazuddin Saraf S, Saraf S. Recent advances and future prospects of phyto–phospholipid complexation technique for improving pharmacokinetic profile of plant actives. J. Control. Release 168(1), 50–60 (2013).
  Medline CASGoogle Scholar
• 44. Cui F, Shi K, Zhang LQ, Tao AJ, Kawashima Y. Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114(2), 242–250 (2006).
  Medline CASGoogle Scholar
• 45. Ge L, He XY, Zhang YJ et al. A dabigatran etexilate phospholipid complex nanoemulsion system for further oral bioavailability by reducing drug-leakage in the gastrointestinal tract. Nanomedicine 14(4), 1455–1464 (2018).
  CASGoogle Scholar
• 46. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Enhanced therapeutic potential of naringenin-phospholipid complex in rats. J. Pharm. Pharmacol. 58(9), 1227–1233 (2006).
  Medline CASGoogle Scholar
• 47. Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int. J. Pharm. 454(1), 573–583 (2013).
  Medline CASGoogle Scholar
• 48. Nazzal S, Smalyukh II, Lavrentovich OD, Khan MA. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. Int. J. Pharm. 235(1–2), 247–265 (2002).
  Medline CASGoogle Scholar
• 49. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453(1), 198–214 (2013).
  Medline CASGoogle Scholar
• 50. Parmar N, Singla N, Amin S, Kohli K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system. Colloid Surface B 86(2), 327–338 (2011).
  Medline CASGoogle Scholar
• 51. Gurram AK, Deshpande PB, Kar SS, Nayak UY, Udupa N, Reddy MS. Role of components in the formation of self-microemulsifying drug delivery systems. Indian J. Pharm. Sci. 77(3), 249–257 (2015).
  Medline CASGoogle Scholar
• 52. Mcclements DJ, Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity. Crit. Rev. Food Sci. 51(4), 285–330 (2011).
  Medline CASGoogle Scholar
• 53. Das D, Lin SS. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 94(6), 1343–1353 (2005).
  Medline CASGoogle Scholar
• 54. Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J. Pharm. Sci. 10(1), 13–23 (2015).
  Google Scholar
• 55. Englund G, Rorsman F, Ronnblom A et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29(3–4), 269–277 (2006).
  Medline CASGoogle Scholar
• 56. Planas JM, Alfaras I, Colom H, Juan ME. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys 527(2), 67–73 (2012). •• Representative review paper on the role of ABC transporters in the intestinal absorption of trans-resveratrol.
  Medline CASGoogle Scholar
• 57. Chen SF, Zhang J, Wu L, Wu HF, Dai M. Paeonol nanoemulsion for enhanced oral bioavailability: optimization and mechanism. Nanomedicine (Lond). 13(3), 269–282 (2018).
  CASGoogle Scholar